BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a
specialty pharmaceutical company with a focus in the areas of pain management
and addiction medications. Utilizing its proprietary BioErodible MucoAdhesive
(BEMA®) drug delivery technology, the company is developing new applications of
proven therapies aimed at addressing important unmet medical needs. By building
upon previously approved therapeutics, BDSI is able to adhere to a more
time-efficient regulatory pathway, effectively shortening the development
process and providing a streamlined method for the company to pursue its
ultimate goal of enhancing patient care.
The company’s product portfolio includes two unique
treatment options currently approved for commercialization – ONSOLIS®, for the
treatment of breakthrough cancer pain, and BUNAVAIL™, for the treatment of
opioid dependence. In the first quarter of 2015, BDSI made significant progress
with both of these products. In particular, BUNAVAIL recorded a 25 percent
month-over-month growth average in prescription sales throughout the period,
and the company reacquired North American marketing rights for ONSOLIS, clearing
the way for future commercialization.
“We continue to make progress with the launch of BUNAVAIL,”
Dr. Mark A. Sirgo, president and chief executive officer of BDSI, stated in a
news release. “[W]e are making significant advancements in securing managed
care and pharmacy access to BUNAVAIL… providing additional access to over
30,000 prescriptions each month.”
Through the ongoing launch of BUNAVAIL, BDSI gains access to
a large and significantly underserved market within the U.S. pharmaceutical
industry. According to the U.S. Department of Health and Human Services,
approximately 2.5 million people throughout the country are currently dependent
on prescription opioids. As a result, the current market for the treatment of
opioid dependence was estimated at $1.7 billion in 2013, demonstrating the
considerable market potential of BUNAVAIL.
In May, BDSI took a major step toward capitalizing on this
potential through the expansion of its sales and managed markets teams. Through
these hires, the company added valuable sales and managed markets experience
that’s expected to drive substantial growth in both sales and market share in
the months to come.
“We are extremely pleased to have hired a number of key
sales and managed markets personnel previously with Salix, a leader in its
respective field and one driven by a strong commercial sales organization,”
continued Sirgo. “This provides us with a strong sales and managed markets
leadership team as we continue to advance the commercialization of BUNAVAIL.”
For prospective shareholders, BDSI’s favorable product
pipeline should provide a platform for sustainable market growth in the future.
Look for the company to leverage this positioning in order to promote strong
returns moving forward.
For more information, visit www.bdsi.com
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
